The FDA has granted traditional approval to Rubraca (rucaparib) for metastatic castration-resistant prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback